Peroxisome Proliferator-Activated Receptor-γ Is Critical to Cardiac Fibrosis

被引:44
作者
Liu, Huang-Jun [1 ,2 ,3 ]
Liao, Hai-Han [1 ,2 ,3 ]
Yang, Zheng [1 ,2 ,3 ]
Tang, Qi-Zhu [1 ,2 ,3 ]
机构
[1] Wuhan Univ, Renmin Hosp, Dept Cardiol, Wuhan 430060, Peoples R China
[2] Wuhan Univ, Cardiovasc Res Inst, Wuhan 430060, Peoples R China
[3] Hubei Key Lab Cardiol, Wuhan 430060, Peoples R China
基金
中国国家自然科学基金;
关键词
ATRIAL-FIBRILLATION PROMOTION; LEFT-VENTRICULAR HYPERTROPHY; PPAR-GAMMA; MYOCARDIAL FIBROSIS; HEART-FAILURE; DIABETIC CARDIOMYOPATHY; CARDIOVASCULAR-DISEASE; NATRIURETIC PEPTIDE; TYPE-1; RECEPTOR; DOWN-REGULATION;
D O I
10.1155/2016/2198645
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Peroxisome proliferator-activated receptor-gamma (PPAR gamma) is a ligand-activated transcription factor belonging to the nuclear receptor superfamily, which plays a central role in regulating lipid and glucose metabolism. However, accumulating evidence demonstrates that PPAR gamma agonists have potential to reduce inflammation, influence the balance of immune cells, suppress oxidative stress, and improve endothelial function, which are all involved in the cellular and molecular mechanisms of cardiac fibrosis. Thus, in this review we discuss the role of PPAR gamma in various cardiovascular conditions associated with cardiac fibrosis, including diabetes mellitus, hypertension, myocardial infarction, heart failure, ischemia/reperfusion injury, atrial fibrillation, and several other cardiovascular disease (CVD) conditions, and summarize the developmental status of PPAR gamma agonists for the clinical management of CVD.
引用
收藏
页数:12
相关论文
共 106 条
[1]   Effects of rosiglitazone (PPAR γ agonist) on the myocardium in non-hypertensive diabetic rats [J].
Abou Daya, Khodor ;
Abu Daya, Hussein ;
Eddine, Mohamad Nasser ;
Nahhas, Georges ;
Nuwayri-Salti, Nuha .
JOURNAL OF DIABETES, 2015, 7 (01) :85-94
[2]  
Azhar S, 2010, FUTUR CARDIOL, V6, P657, DOI [10.2217/fca.10.86, 10.2217/FCA.10.86]
[3]   Pioglitazone limits myocardial infarct size, activates Akt, and upregulates cPLA2 and COX-2 in a PPAR-γ-independent manner [J].
Birnbaum, Yochai ;
Long, Bo ;
Qian, Jinqiao ;
Perez-Polo, Jose R. ;
Ye, Yumei .
BASIC RESEARCH IN CARDIOLOGY, 2011, 106 (03) :431-446
[4]   Reactivation of Snail genes in renal fibrosis and carcinomas -: A process of reversed embryogenesis? [J].
Boutet, Agnes ;
Esteban, Miguel A. ;
Maxwell, Patrick H. ;
Angela Nieto, M. .
CELL CYCLE, 2007, 6 (06) :638-642
[5]   The cardiac fibroblast: Therapeutic target in myocardial remodeling and failure [J].
Brown, RD ;
Ambler, SK ;
Mitchell, MD ;
Long, CS .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2005, 45 :657-687
[6]   Atrial fibrosis: Mechanisms and clinical relevance in atrial fibrillation [J].
Burstein, Brett ;
Nattel, Stanley .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 51 (08) :802-809
[7]   A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes [J].
Candido, R ;
Forbes, JM ;
Thomas, MC ;
Thallas, V ;
Dean, RG ;
Burns, WC ;
Tikellis, C ;
Ritchie, RH ;
Twigg, SM ;
Cooper, ME ;
Burrell, LM .
CIRCULATION RESEARCH, 2003, 92 (07) :785-792
[8]  
Chello M, 1996, J CARDIOVASC SURG, V37, P229
[9]   Osthole Regulates TGF-β1 and MMP-2/9 Expressions via Activation of PPARα/γ in Cultured Mouse Cardiac Fibroblasts Stimulated with Angiotensin II [J].
Chen, Rong ;
Xue, Jie ;
Xie, Meilin .
JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, 2013, 16 (05) :732-741
[10]   Puerarin prevents isoprenaline-induced myocardial fibrosis in mice by reduction of myocardial TGF-β1 expression [J].
Chen, Rong ;
Xue, Jie ;
Xie, Meilin .
JOURNAL OF NUTRITIONAL BIOCHEMISTRY, 2012, 23 (09) :1080-1085